EVO-002

EVO-002 is a novel protein therapeutic candidate developed by Evozyne for the treatment of inflammatory bowel disease (IBD), specifically ulcerative colitis. The molecule was engineered using Evozyne's proprietary generative AI platform, which utilizes deep learning and evolutionary data to design optimized proteins with specific functional properties. As of mid-2026, the program is in the IND-enabling phase of development, progressing toward clinical trials. The specific biological target and mechanism of action have not been publicly disclosed, but the drug is intended to modulate inflammatory pathways associated with chronic intestinal inflammation.